

# Luncheon Symposium 3

---

## Chairperson

---

**Yong Sung Kim**  
Design Hospital, Korea

---

## Speaker

---

**Jun Hwa Hong**  
Eulji University, Korea



## Jun Hwa Hong

Eulji University, Korea

### • Education

Period	Affiliation	Position
– 2015	Eulji University	Ph.D.
– 2008	Eulji University	M.Sc.
– 2004	Eulji University	M.D.

### • Affiliations / Experience

Period	Affiliation	Position
– Present	Eulji University Hospital, Korea	Associate Professor
– 2023	Eulji University Hospital, Korea	Assistant Professor
– 2017	Kyungpook National University Hospital, Korea	Clinical Assistant Professor
– 2015	Chungnam National University Hospital	Fellowship

### • Committee Memberships

- The Korean Society for the Study of Obesity
- The Korean Endocrine Society
- The Korean Diabetes Association
- The Daejeon Chungcheong Division of Korean Endocrine Society

### • Publications

- Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: third agent study. *Diabetes Res Clin Pract.* 2023 Aug 11;110872. doi: 10.1016/j.diabres.2023.110872
- Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study. *Diabetes Obes Metab.* 2023 Aug;25(8):2181-2190. doi: 10.1111/dom.15095. Epub 2023 May 3
- A randomized, active-controlled, parallel, open-label, multicenter, phase 4 study to compare the efficacy and safety of pregabalin sustained release tablet and pregabalin immediate release capsule in type II diabetic patients with peripheral neuropathic pain. *Medicine (Baltimore).* 2023 Apr 25;102(17):e33701
- Effects of Virtual Reality Exercise Program on Blood Glucose, Body Composition, and Exercise Immersion in Patients with Type 2 Diabetes. *Int. J. Environ. Res. Public Health* 2023, 20(5), 4178
- SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease: *Trends Endocrinol Metab.* 2022 Jun;33(6):424-442. doi: 10.1016/j.tem.2022.03.005. Epub 2022 Apr 28

### Luncheon Symposium 3

## The Earlier Use of SGLT2i, The Better Clinical Outcome in Obese T2D

Jun Hwa Hong (Eulji University, Korea)

---

Many pharmacotherapies are now available for glycaemic control in type 2 diabetes (T2D); however, the management of T2D remains complex and challenging, in part due to the limiting side effects of current therapies as well as the variable pathogenesis and progressive natural history of T2D. Thus, the quest to develop therapeutic agents with novel mechanisms of action that might fulfill the unmet needs of the currently available therapies continues. While several novel therapies for T2D are indeed on the horizon, dipeptidyl peptidase-4 inhibitors (DPP4is) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are the most recently introduced novel classes of antihyperglycaemic drugs.

Combination therapy with SGLT2i and DPP4i is both efficacious and safe. In particular, a marked additional glucose-lowering effect is evident when SGLT2i is combined with or added to DPP4i. Additional benefits of combination therapy are cardiorenal protection and metabolic improvement of both class of drugs. This combination therapy is The harmony for holistic treatment of type 2 diabetes.